View Older Stories View More Recent Stories
-
Novo Nordisk (NVO) call put ratio 1.7 calls to 1 put into quarter results
-
Novo Nordisk (NVO) call put ratio 1.5 calls to 1 put into quarter results
-
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
-
Novo Nordisk (NVO) Faces Securities Class Action After Weight Loss Therapy Trial Data Disappoints, Analyst Questions Trial's Design - Hagens Berman
-
NVO INVESTOR NOTICE: Novo Nordisk A/S Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
ROSEN, A TOP RANKED LAW FIRM, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO
-
Eli Lilly & Co. (LLY), Novo (NVO) see mid-day upside
-
NVO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Novo Nordisk A/S Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
-
BMO Capital Reiterates Outperform Rating on Novo Nordisk (NVO) following latest Ozempic approval
-
FDA approves Novo Nordisk's (NVO) Ozempic as the only GLP-1 RA to reduce the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and CKD
-
Novo Nordisk (NVO) sees pre-open selling pressure
-
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
-
BofA Securities Reiterates Buy Rating on Eli Lilly (LLY)
-
BMO Capital Reiterates Outperform Rating on Novo Nordisk (NVO) Amid Solid SubQ Amycretin Results
-
Novo Nordisk (NVO) successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity
-
Novo Nordisk (NVO) call put ratio 1 call to 1 put into share price up before the bell
-
Novo Nordisk (NVO) call put ratio 2.5 calls to 1 put
-
BofA Securities Reiterates Buy Rating on Novo Nordisk (NOVOB:DC) (NVO)
-
Novo Nordisk (NVO) PT Lowered to $90 at CFRA
-
BofA Securities Reiterates Buy Rating on Novo Nordisk (NOVOB:DC) (NVO)
-
Novo's (NVO) Ozempic, Wegovy Targeted In Medicare Price Negotiations - Bloomberg
-
Novo Nordisk (NOVOB:DC) (NVO) PT Raised to DKK798 at Guggenheim
-
Novo Nordisk (NVO) : Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence
-
Novo Nordisk (NVO) call put ratio 1 call to 1 put as share price pulls back
-
Novo Nordisk (NVO) and Valo Health expand collaboration to discover and develop novel treatments for cardiometabolic diseases
-
UBS Upgrades Novo Nordisk (NOVOB:DC) (NVO) to Buy
-
TD Cowen on Pharma: '10 Events in 2025 That Could Change Practice, Alter Companies, Move Stocks'
-
Bernstein SocGen Group Upgrades Novo Nordisk (NOVOB:DC) (NVO) to Market Perform
-
TD Cowen on Trump Tariffs and Other Risks: 'Where Does Pharma Stand?'
-
Novo Nordisk (NVO) PT Lowered to $105 at BMO Capital
-
Novo Nordisk (NVO) options active on 195K contracts amid sharp move lower
-
KeyBanc Weighs in on GLP-1 Injection Leaders Following Latest NVO Results
-
Bernstein SocGen Group Reiterates Underperform Rating on Novo Nordisk (NOVOB:DC) (NVO)
-
Novo Nordisk (NVO) January 3 weekly 110 and June 115 calls active as share price down 17.8% after releasing Cagrisema data
-
Novo Nordisk (NVO) PT Lowered to $105 at BMO Capital
-
Novo Nordisk (NVO) call put ratio 1.7 calls to 1 put after releasing Cagrisema data
-
Viking Therapeutics (VKTX), Others Gain After Novo Nordisk (NVO) Data Falls Short of Expectations
-
Novo Nordisk (NVO) reports data from CagriSema REDEFINE 1 trial
-
Hims & Hers Health (HIMS) Quickly Falls 9% after FDA Says the Obesity Drug Shortage Ended
-
Novo Nordisk (NVO) Completes $16.5B Acquisition of Catalent
-
CFRA Starts Novo Nordisk (NVO) at Hold
-
Ozempic Study Found Small Number Of Patients With Vision Loss - Bloomberg
-
Bernstein: 'GLP-1s vs. the Weight of the World'
-
Buy this fast-growing European pharma stock, TD Cowen says
-
TD Cowen Reiterates Buy Rating on Novo Nordisk (NVO); Stock Named Best Idea 2025
-
Bernstein: 'Could the lion's share of China GLP-1 market go to domestic players?'
-
3 catalysts that could send this GLP-1 stock surging: BofA
-
Catalent (CTLT) and Novo Holdings (NVO) Receive European Commission Unconditional Approval for Pending Transaction
-
BMO Capital: Five Key BioPharma Catalysts Through Year-End '24

